Vincent arrived at Wasdell with over 20 years’ experience in senior roles within the pharmaceutical sector, leaving his position at Shire Pharmaceuticals, where he was vice president of global materials management and international supply chain for almost a decade.
As CEO, Vincent will sit on the company’s board of directors. Previous CEO, Martin Tedham has taken on a new role as the Chairman of the group.
Martin said: “We are delighted to have Vincent on board at Wasdell. He brings invaluable experience and expertise to help support the next phases of our expansion. The company has grown over 45% in the last two years and with our plans to expand our offering even further over the coming years, we could not wish for a better time to strengthen our leadership team.
“The company has transformed in recent years, and it is clear we are becoming more established within the life science sector as a go-to outsourcing partner for its end-to-end supply needs. I am extremely proud of where we have come and what the future holds with Vincent at the helm.”
In his new role, Vincent will be responsiblefor driving the strategic direction of the group, as the company expands further.
Commenting on his appointment, Vincent said: “I am thrilled to be joining the Wasdell Group at such a pivotal time of growth and investment, namely the launch of our Dundalk facility, expansion in Swindon and adding new manufacturing capabilities at our Newcastle site.
“Another key focus will be managing existing operations so that we can continue to support customers’ supply chains across the globe with high-quality service and unrivalled lead times.”
As part of the senior management restructure, Daniel Tedham, has also been promoted to Group managing director, taking over responsibilities for sites in Newcastle, Swindon and Burnley, ahead of forecasted growth, which is estimated to increase by 25% by 2020.
The group offers a range of technical, manufacturing, packaging and storage and distribution services and its recent major investments include building its first site outside of the UK, expanding its clinical capabilities across all phases and adding an on-site laboratory at its Newcastle site.